Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 2,413 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dysplasia Mild Clear all

Conditions: Primary Open-Angle Glaucoma
Interventions: TECNIS PureSee Intraocular Lens, TECNIS ZCB00 Monofocal Intraocular Lens; Device
Lead sponsor: Mann Eye Institute; Other
Eligibility: 45 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Primary Open Angle Glaucoma
Interventions: Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device, Cataract surgery; Device · Procedure
Lead sponsor: Nova Eye, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Parkinson Disease
Interventions: Placebo, Varenicline; Drug
Lead sponsor: Vikas Kotagal; Other
Eligibility: 45 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Atopic Dermatitis
Interventions: Crisaborole 2% Top Oint; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 2 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Interventions: Beta amyloid imaging; Device
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 315 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID-19
Interventions: Leflunomide; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Brain Concussion, Pediatric, Mild Traumatic Brain Injury, Psychological
Interventions: Sub symptom aerobic exercise; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 10 Years to 18 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Dementia With Lewy Bodies, Parkinson Disease Dementia, Healthy Controls
Interventions: Syn-One skin biopsy, Multi modal MRI, Assessment of dynamic EEG features over 48-hour periods across all study aims, Plasma biomarkers, Galantamine HBr extended-release 8mg capsules (8mg ER).; Procedure · Diagnostic Test · Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 50 Years to 89 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Dyslipidemias, High Cholesterol, Hypercholesterolemia
Interventions: Obicetrapib 5mg, Ezetimibe 10mg, Placebo; Drug · Other
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 3
States / cities: Lincoln, California • Evanston, Illinois • Houston, Texas

Conditions: Alzheimer's Disease
Interventions: CERE-110: Adeno-Associated Virus Delivery of NGF; Genetic
Lead sponsor: Sangamo Therapeutics; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 2
States / cities: San Diego, California • Chicago, Illinois

Conditions: AMCI - Amnestic Mild Cognitive Impairment, Sleep Disturbance
Interventions: Trazodone, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 55 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Mild Cognitive Impairment (MCI), Alzheimer Disease, Alzheimer's Disease (Incl Subtypes), Dementia, Cognitive Decline
Interventions: Acceptability and Feasibility of Twistle messaging for PDM+ patients; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 65 Years and older
Enrollment: 3,454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Mild Traumatic Brain Injury
Interventions: Active CN-NINM PoNS, Sham CN-NINM PoNS; Device
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Richmond, Virginia

Conditions: Atopic Dermatitis
Interventions: Non-medicated Emollient plus Lyocell/Chitosan Sleeve, Non-medicated Emollient plus Cotton Sleeve, Placebo Sleeve; Device · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 3 Months to 5 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Renal Impairment
Interventions: Elinogrel; Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Knoxville, Tennessee

Conditions: COVID-19
Interventions: Belnacasan, Placebo; Drug
Lead sponsor: MedStar Health; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Alzheimer's Disease
Interventions: Dimebon, Placebo; Drug
Lead sponsor: Medivation, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 598 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 28
States / cities: Phoenix, Arizona • Costa Mesa, California • Fresno, California + 25 more

Conditions: Dementia, Potentially Inappropriate Medication Use, Mild Cognitive Impairment (MCI)
Interventions: e-ALIGN Patient-Portal Deprescribing; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Concussion, Mild Traumatic Brain Injury
Interventions: Post-mTBI Educational Resource; Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 8 Years to 99 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 3
States / cities: Frisco, Texas • Temple, Texas

Conditions: Alzheimer Disease, Dementia, Mild Cognitive Impairment, Cognitive Decline
Interventions: MindMate + Health Coaching, Health Education; Behavioral · Other
Lead sponsor: Neurotrack Technologies, Inc.; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Psoriasis
Interventions: Luma Light System, Luma Light, Occlusive Dressing; Device
Lead sponsor: Illumicure Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 1
States / cities: Santa Rosa, California

Conditions: Mild Traumatic Brain Injury, Gait, Balance, Veterans, Mobility
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 6
States / cities: Fort Carson, Colorado • Minneapolis, Minnesota • Portland, Oregon + 3 more

Conditions: Mild-moderate Unipolar Depression; Persistent Negative Affect
Interventions: Mindfulness-Based Cognitive Therapy, Focused Attention (FA), Open- Monitoring; Behavioral
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Alzheimer's Disease
Interventions: Intravenous Immunoglobulin, Placebo; Drug · Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 50 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

PureSee EDOF Versus ZCB00 Monofocal IOLs in Mild-to-Moderate Glaucoma

Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma

Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease

Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis

Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.

Leflunomide in Mild COVID-19 Patients

Early Exercise to Improve Psychosocial Function After Pediatric Mild Traumatic Brain Injury

Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia

Randomized Study of Obicetrapib in Combination With Ezetimibe

CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone

Innovative Cognitive Impairment Case Finding and Engagement for Diverse Participation in Alzheimer's Disease Care, Treatment, And Research

Cranial-nerve Non-invasive Neuromodulation (CN-NINM) for Balance Deficits After Mild Traumatic Brain Injury (Full Trial)

Study to Examine the Benefits of Fabric Made With Lyocell/Chitosan/Ceramide in the Treatment of Children With Mild to Moderate Eczema

Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment

Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19

A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease

e-ALIGN: A Patient Portal-based Intervention to Align Medications With What Matters Most

Implementation of an Evidence-Based Educational Resource for Children With Mild Traumatic Brain Injury

Reducing Dementia Risk With Digital Health Coaching

Luma Light System Proof of Concept Study in Subjects With Mild to Moderate Psoriasis

Objective Dual-task Turning Measures for Return-to-duty Assessments

Dismantling Mindfulness: Contributions of Attention vs. Acceptance

Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease